Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1659 participants.
Also called NCT02603809
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,659 participants
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- Registry
-
NCT02603809
-
- Other papers using this trial's data
- Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Israel, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02603809. Randomized; quadruple masking; primary purpose treatment. Start 2015-12-14 (actual); primary completion 2017-02-28 (actual). Results posted on 2020-04-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Aprocitentan 5 mg
- Intervention (Drug)
- Aprocitentan 10 mg
- Intervention (Drug)
- Aprocitentan 25 mg
- Intervention (Drug)
- Aprocitentan 50 mg
- Intervention (Drug)
- Lisinopril 20 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
Record details
- Record id
cardio:ct-nct02603809- Content hash
82d46d8c385a45341d316e92b82fcdef0f4a407014fb836a15ca8c83197c1c37